CryoPort, Inc. Begins Production of the CryoPort Express Shipper(TM)

Company Begins Inventory Build-Up

LAKE FOREST, CA -- (MARKET WIRE) -- 12/06/07 -- CryoPort, Inc. (OTCBB: CYRX) today announced that it has begun production of the CryoPort Express Shipper and is currently building inventory. This marks the start of the next phase in the Company's development plan.

Peter Berry, CEO of CryoPort, commented, "After several weeks of testing, we are fully satisfied with both our production process and the quality of our product. We have begun the sales and marketing process and are in current discussions with several potential significant customers in the biopharmaceutical and clinical trial's industries. Additional meetings are planned in the coming weeks and we will be providing further information and detail as it becomes available to us."

Peter Berry continued, "We are extremely pleased that we were able to get our production facility up and running as quickly as we did. We believe that we are now in a position to capitalize on the growing concerns of healthcare agencies about the need to maintain proper and validated temperature controls over sensitive materials, such as vaccines."

About CryoPort, Inc.

CryoPort ( develops leading edge, proprietary, technology-driven shipping and storage products for use in the rapidly growing global biotechnology and biopharmaceutical cold chain. The products developed by CryoPort are essential components of the infrastructure required for the testing, research and end user delivery of temperature-sensitive medicines and biomaterials in an increasingly complex logistical environment.


This press release contains forward-looking statements. The words "estimate," "possible" and "seeking" and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Stuart Fine
Carpe DM, Inc.